Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Depomed has announced top-line results from Breeze 3, a Phase 3 trial that assessed the efficacy and safety of Serada for menopausal hot flashes.
Subscribe to our email newsletter
Serada is an extended-release, orally administered formulation of gabapentin for the treatment of menopausal hot flashes which uses the company’s Acuform drug delivery technology.
Breeze 3, a randomized, double-blind, placebo-controlled 24 week study comprised 600 women who were randomized into one of two treatment arms, one receiving either placebo or a total dose of 1800mg of Serada dosed at 600mg in the morning and 1200mg in the evening.
The co-primary efficacy endpoints showed reductions in the average daily frequency and severity of moderate-to-severe hot flashes, measured after four and 12 weeks of treatment.
Based on the data from this trial combined with the data from Breeze 1 and 2 Phase 3 trials, the company plans to review the results with the US FDA to file a new drug application (NDA).